News

Investors might want to bet on Nuvation Bio Inc. (NUVB), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities ...
The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and aggressive form of lung cancer.
Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock here on Seeking Alpha.
NEW YORK, August 05, 2024--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial ...
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors ...
Nuvation Bio's IBTROZI received FDA approval for ROS1+ NSCLC, but the stock dropped sharply due to mandated costly post-marketing trials and high SG&A expenses. Despite a strong cash position and ...
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer ...
--Nuvation Bio Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology ...
Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.